Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 51

1.

The Use of Targeted Next Generation Sequencing to Explore Candidate Regulators of TGF-β1's Impact on Kidney Cells.

Wang B, Ji G, Naeem H, Wang J, Kantharidis P, Powell D, Ricardo SD.

Front Physiol. 2018 Dec 10;9:1755. doi: 10.3389/fphys.2018.01755. eCollection 2018.

2.

Lipoxins Protect Against Inflammation in Diabetes-Associated Atherosclerosis.

Brennan EP, Mohan M, McClelland A, de Gaetano M, Tikellis C, Marai M, Crean D, Dai A, Beuscart O, Derouiche S, Gray SP, Pickering R, Tan SM, Godson-Treacy M, Sheehan S, Dowdall JF, Barry M, Belton O, Ali-Shah ST, Guiry PJ, Jandeleit-Dahm K, Cooper ME, Godson C, Kantharidis P.

Diabetes. 2018 Dec;67(12):2657-2667. doi: 10.2337/db17-1317. Epub 2018 Sep 13.

3.

Lipoxins Regulate the Early Growth Response-1 Network and Reverse Diabetic Kidney Disease.

Brennan EP, Mohan M, McClelland A, Tikellis C, Ziemann M, Kaspi A, Gray SP, Pickering R, Tan SM, Ali-Shah ST, Guiry PJ, El-Osta A, Jandeleit-Dahm K, Cooper ME, Godson C, Kantharidis P.

J Am Soc Nephrol. 2018 May;29(5):1437-1448. doi: 10.1681/ASN.2017101112. Epub 2018 Feb 28.

4.

RAGE Deletion Confers Renoprotection by Reducing Responsiveness to Transforming Growth Factor-β and Increasing Resistance to Apoptosis.

Hagiwara S, Sourris K, Ziemann M, Tieqiao W, Mohan M, McClelland AD, Brennan E, Forbes J, Coughlan M, Harcourt B, Penfold S, Wang B, Higgins G, Pickering R, El-Osta A, Thomas MC, Cooper ME, Kantharidis P.

Diabetes. 2018 May;67(5):960-973. doi: 10.2337/db17-0538. Epub 2018 Feb 15.

5.

Perinatal exposure to high dietary advanced glycation end products in transgenic NOD8.3 mice leads to pancreatic beta cell dysfunction.

Borg DJ, Yap FYT, Keshvari S, Simmons DG, Gallo LA, Fotheringham AK, Zhuang A, Slattery RM, Hasnain SZ, Coughlan MT, Kantharidis P, Forbes JM.

Islets. 2018 Jan 2;10(1):10-24. doi: 10.1080/19382014.2017.1405189. Epub 2017 Dec 22.

6.

Increased liver AGEs induce hepatic injury mediated through an OST48 pathway.

Zhuang A, Yap FY, Bruce C, Leung C, Plan MR, Sullivan MA, Herath C, McCarthy D, Sourris KC, Kantharidis P, Coughlan MT, Febbraio MA, Hodson MP, Watt MJ, Angus P, Schulz BL, Forbes JM.

Sci Rep. 2017 Sep 25;7(1):12292. doi: 10.1038/s41598-017-12548-4.

7.

Protective Effect of let-7 miRNA Family in Regulating Inflammation in Diabetes-Associated Atherosclerosis.

Brennan E, Wang B, McClelland A, Mohan M, Marai M, Beuscart O, Derouiche S, Gray S, Pickering R, Tikellis C, de Gaetano M, Barry M, Belton O, Ali-Shah ST, Guiry P, Jandeleit-Dahm KAM, Cooper ME, Godson C, Kantharidis P.

Diabetes. 2017 Aug;66(8):2266-2277. doi: 10.2337/db16-1405. Epub 2017 May 9.

8.

Diabetic Nephropathy: Proteinuria, Inflammation, and Fibrosis.

Zheng S, Powell DW, Zheng F, Kantharidis P, Gnudi L.

J Diabetes Res. 2016;2016:5241549. doi: 10.1155/2016/5241549. Epub 2016 Jan 6. No abstract available.

9.

miR-21 promotes renal fibrosis in diabetic nephropathy by targeting PTEN and SMAD7.

McClelland AD, Herman-Edelstein M, Komers R, Jha JC, Winbanks CE, Hagiwara S, Gregorevic P, Kantharidis P, Cooper ME.

Clin Sci (Lond). 2015 Dec;129(12):1237-49. doi: 10.1042/CS20150427. Epub 2015 Sep 28.

PMID:
26415649
10.

Study of microRNA in diabetic nephropathy: isolation, quantification and biological function.

Kantharidis P, Hagiwara S, Brennan E, McClelland AD.

Nephrology (Carlton). 2015 Mar;20(3):132-9. doi: 10.1111/nep.12374. Review.

PMID:
25487691
11.

Ramipril inhibits AGE-RAGE-induced matrix metalloproteinase-2 activation in experimental diabetic nephropathy.

Fukami K, Yamagishi S, Coughlan MT, Harcourt BE, Kantharidis P, Thallas-Bonke V, Okuda S, Cooper ME, Forbes JM.

Diabetol Metab Syndr. 2014 Aug 13;6(1):86. doi: 10.1186/1758-5996-6-86. eCollection 2014.

12.

Transcriptome-based analysis of kidney gene expression changes associated with diabetes in OVE26 mice, in the presence and absence of losartan treatment.

Komers R, Xu B, Fu Y, McClelland A, Kantharidis P, Mittal A, Cohen HT, Cohen DM.

PLoS One. 2014 May 14;9(5):e96987. doi: 10.1371/journal.pone.0096987. eCollection 2014.

13.

MicroRNA in diabetic nephropathy: renin angiotensin, aGE/RAGE, and oxidative stress pathway.

Hagiwara S, McClelland A, Kantharidis P.

J Diabetes Res. 2013;2013:173783. doi: 10.1155/2013/173783. Epub 2013 Dec 15. Review.

14.

Where are we in diabetic nephropathy: microRNAs and biomarkers?

McClelland A, Hagiwara S, Kantharidis P.

Curr Opin Nephrol Hypertens. 2014 Jan;23(1):80-6. doi: 10.1097/01.mnh.0000437612.50040.ae. Review.

PMID:
24247820
15.

Transforming growth factor-β1-mediated renal fibrosis is dependent on the regulation of transforming growth factor receptor 1 expression by let-7b.

Wang B, Jha JC, Hagiwara S, McClelland AD, Jandeleit-Dahm K, Thomas MC, Cooper ME, Kantharidis P.

Kidney Int. 2014 Feb;85(2):352-61. doi: 10.1038/ki.2013.372. Epub 2013 Oct 2.

16.

microRNA in the development of diabetic complications.

McClelland AD, Kantharidis P.

Clin Sci (Lond). 2014 Jan;126(2):95-110. doi: 10.1042/CS20130079. Review.

PMID:
24059587
17.

MicroRNA as biomarkers and regulator of cardiovascular development and disease.

Hagiwara S, Kantharidis P, Cooper ME.

Curr Pharm Des. 2014;20(14):2347-70. Review.

PMID:
23844813
18.

What are new avenues for renal protection, in addition to RAAS inhibition?

Hagiwara S, Kantharidis P, Cooper ME.

Curr Hypertens Rep. 2012 Apr;14(2):100-10. doi: 10.1007/s11906-012-0251-1. Review.

PMID:
22298106
19.

Advanced glycation end products as environmental risk factors for the development of type 1 diabetes.

Yap FY, Kantharidis P, Coughlan MT, Slattery R, Forbes JM.

Curr Drug Targets. 2012 Apr;13(4):526-40. Review.

PMID:
22250649
20.

Suppression of microRNA-29 expression by TGF-β1 promotes collagen expression and renal fibrosis.

Wang B, Komers R, Carew R, Winbanks CE, Xu B, Herman-Edelstein M, Koh P, Thomas M, Jandeleit-Dahm K, Gregorevic P, Cooper ME, Kantharidis P.

J Am Soc Nephrol. 2012 Feb;23(2):252-65. doi: 10.1681/ASN.2011010055. Epub 2011 Nov 17.

21.

Magnetic silica spheres with large nanopores for nucleic acid adsorption and cellular uptake.

Liu J, Wang B, Hartono SB, Liu T, Kantharidis P, Middelberg AP, Lu GQ, He L, Qiao SZ.

Biomaterials. 2012 Jan;33(3):970-8. doi: 10.1016/j.biomaterials.2011.10.001. Epub 2011 Oct 22.

PMID:
22019119
22.

The role of EMT in renal fibrosis.

Carew RM, Wang B, Kantharidis P.

Cell Tissue Res. 2012 Jan;347(1):103-16. doi: 10.1007/s00441-011-1227-1. Epub 2011 Aug 16. Review.

PMID:
21845400
23.

Diabetes complications: the microRNA perspective.

Kantharidis P, Wang B, Carew RM, Lan HY.

Diabetes. 2011 Jul;60(7):1832-7. doi: 10.2337/db11-0082. Review. No abstract available.

24.

Osteoprotegerin promotes vascular fibrosis via a TGF-β1 autocrine loop.

Toffoli B, Pickering RJ, Tsorotes D, Wang B, Bernardi S, Kantharidis P, Fabris B, Zauli G, Secchiero P, Thomas MC.

Atherosclerosis. 2011 Sep;218(1):61-8. doi: 10.1016/j.atherosclerosis.2011.05.019. Epub 2011 May 27.

PMID:
21679949
25.

Dedifferentiation of immortalized human podocytes in response to transforming growth factor-β: a model for diabetic podocytopathy.

Herman-Edelstein M, Thomas MC, Thallas-Bonke V, Saleem M, Cooper ME, Kantharidis P.

Diabetes. 2011 Jun;60(6):1779-88. doi: 10.2337/db10-1110. Epub 2011 Apr 26.

26.

TGF-beta regulates miR-206 and miR-29 to control myogenic differentiation through regulation of HDAC4.

Winbanks CE, Wang B, Beyer C, Koh P, White L, Kantharidis P, Gregorevic P.

J Biol Chem. 2011 Apr 22;286(16):13805-14. doi: 10.1074/jbc.M110.192625. Epub 2011 Feb 15.

27.

miR-200a Prevents renal fibrogenesis through repression of TGF-β2 expression.

Wang B, Koh P, Winbanks C, Coughlan MT, McClelland A, Watson A, Jandeleit-Dahm K, Burns WC, Thomas MC, Cooper ME, Kantharidis P.

Diabetes. 2011 Jan;60(1):280-7. doi: 10.2337/db10-0892. Epub 2010 Oct 15.

28.

E-cadherin expression is regulated by miR-192/215 by a mechanism that is independent of the profibrotic effects of transforming growth factor-beta.

Wang B, Herman-Edelstein M, Koh P, Burns W, Jandeleit-Dahm K, Watson A, Saleem M, Goodall GJ, Twigg SM, Cooper ME, Kantharidis P.

Diabetes. 2010 Jul;59(7):1794-802. doi: 10.2337/db09-1736. Epub 2010 Apr 14.

29.

Quantitative gene expression analysis in kidney tissues.

Tikellis C, Koh P, Burns W, Kantharidis P.

Methods Mol Biol. 2009;466:83-107. doi: 10.1007/978-1-59745-352-3_7.

PMID:
19148599
30.

The role of tubular epithelial-mesenchymal transition in progressive kidney disease.

Burns WC, Kantharidis P, Thomas MC.

Cells Tissues Organs. 2007;185(1-3):222-31. Review.

PMID:
17587828
31.

Connective tissue growth factor plays an important role in advanced glycation end product-induced tubular epithelial-to-mesenchymal transition: implications for diabetic renal disease.

Burns WC, Twigg SM, Forbes JM, Pete J, Tikellis C, Thallas-Bonke V, Thomas MC, Cooper ME, Kantharidis P.

J Am Soc Nephrol. 2006 Sep;17(9):2484-94. Epub 2006 Aug 16.

32.

C-terminal domain of insulin-like growth factor (IGF) binding protein-6: structure and interaction with IGF-II.

Headey SJ, Keizer DW, Yao S, Brasier G, Kantharidis P, Bach LA, Norton RS.

Mol Endocrinol. 2004 Nov;18(11):2740-50. Epub 2004 Aug 12.

PMID:
15308688
33.

The role of advanced glycation in reduced organic cation transport associated with experimental diabetes.

Thomas MC, Tikellis C, Kantharidis P, Burns WC, Cooper ME, Forbes JM.

J Pharmacol Exp Ther. 2004 Nov;311(2):456-66. Epub 2004 Jun 22.

PMID:
15213250
34.

Reduced tubular cation transport in diabetes: prevented by ACE inhibition.

Thomas MC, Tikellis C, Burns WC, Thallas V, Forbes JM, Cao Z, Osicka TM, Russo LM, Jerums G, Ghabrial H, Cooper ME, Kantharidis P.

Kidney Int. 2003 Jun;63(6):2152-61.

35.

1H, 13C and 15N resonance assignments of the C-terminal domain of insulin-like growth factor binding protein-6 (IGFBP-6).

Headey SJ, Yao S, Parker NJ, Kantharidis P, Bach LA, Norton RS.

J Biomol NMR. 2003 Mar;25(3):251-2. No abstract available.

PMID:
12652138
36.

MRP1 not MDR1 gene expression is the predominant mechanism of acquired multidrug resistance in two prostate carcinoma cell lines.

Zalcberg J, Hu XF, Slater A, Parisot J, El-Osta S, Kantharidis P, Chou ST, Parkin JD.

Prostate Cancer Prostatic Dis. 2000 Aug;3(2):66-75.

37.
38.

Regulation of MDR1 gene expression: emerging concepts.

Kantharidis P, El-Osta S, Silva M, Lee G, Hu XF, Zalcberg J.

Drug Resist Updat. 2000 Apr;3(2):99-108.

PMID:
11498374
39.

Absolute quantitation of MDR1 transcripts using heterologous DNA standards--validation of the competitive RT-PCR (CRT-PCR) approach.

el-Osta A, Kantharidis P, Zalcberg J.

Biotechniques. 1999 Jun;26(6):1114-6, 1118-20, 1122 passim.

40.

Altered multidrug resistance phenotype caused by anthracycline analogues and cytosine arabinoside in myeloid leukemia.

Hu XF, Slater A, Kantharidis P, Rischin D, Juneja S, Rossi R, Lee G, Parkin JD, Zalcberg JR.

Blood. 1999 Jun 15;93(12):4086-95.

41.

Physical mapping of a tandem duplication on the long arm of chromosome 7 associated with a multidrug resistant phenotype.

de Silva MG, Kantharidis P, Scherer SW, Rayeroux K, Campbell L, Tsui LC, Zalcberg JR.

Cancer Genet Cytogenet. 1999 Apr;110(1):28-33.

PMID:
10198619
42.

Induction of MDR1 gene expression by anthracycline analogues in a human drug resistant leukaemia cell line.

Hu XF, Slater A, Rischin D, Kantharidis P, Parkin JD, Zalcberg J.

Br J Cancer. 1999 Feb;79(5-6):831-7.

43.

Altered methylation of the human MDR1 promoter is associated with acquired multidrug resistance.

Kantharidis P, El-Osta A, deSilva M, Wall DM, Hu XF, Slater A, Nadalin G, Parkin JD, Zalcberg JR.

Clin Cancer Res. 1997 Nov;3(11):2025-32.

44.

Sequential extraction of DNA and DNA-binding proteins from low cell numbers.

el-Osta S, Kantharidis P, Zalcberg JR.

Biotechniques. 1997 Apr;22(4):645-8. No abstract available.

45.

Expression of mdr1 and mrp in the normal B-cell homologue of B-cell chronic lymphocytic leukaemia.

Wall DM, el-Osta S, Tzelepis D, Bertoncello I, Kantharidis P, Chou ST, Zalcberg JR, Parkin JD.

Br J Haematol. 1997 Mar;96(4):697-707.

PMID:
9074409
46.

Cyclosporin A and PSC 833 prevent up-regulation of MDR1 expression by anthracyclines in a human multidrug-resistant cell line.

Hu XF, Slater A, Wall DM, Parkin JD, Kantharidis P, Zalcberg JR.

Clin Cancer Res. 1996 Apr;2(4):713-20.

47.

Inheritance of chromosome 7 is associated with a drug-resistant phenotype in somatic cell hybrids.

de Silva M, Kantharidis P, Wall DM, Campbell L, Vrazas V, Nadalin G, Kaczmarczyk SJ, Hu XF, Parkin JD, Zalcberg JR.

Br J Cancer. 1996 Jan;73(2):169-74.

48.

Rapid up-regulation of mdr1 expression by anthracyclines in a classical multidrug-resistant cell line.

Hu XF, Slater A, Wall DM, Kantharidis P, Parkin JD, Cowman A, Zalcberg JR.

Br J Cancer. 1995 May;71(5):931-6.

49.

Nucleotide sequence of UK bovine rotavirus segment 4: possible host restriction of VP3 genes.

Kantharidis P, Dyall-Smith ML, Tregear GW, Holmes IH.

Virology. 1988 Oct;166(2):308-15.

PMID:
2845645
50.

Marked sequence variation between segment 4 genes of human RV-5 and simian SA 11 rotaviruses.

Kantharidis P, Dyall-Smith ML, Holmes IH.

Arch Virol. 1987;93(1-2):111-21.

PMID:
3028337

Supplemental Content

Loading ...
Support Center